US FDA okays Merck's new once-daily HIV pill
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Subscribe To Our Newsletter & Stay Updated